Old Web
English
Sign In
Acemap
>
authorDetail
>
Yilong Zhang
Yilong Zhang
Novartis
Pasireotide
Medicine
Adverse effect
Pharmacokinetics
Tolerability
3
Papers
50
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Pasireotide (SOM230), a novel multireceptor-targeted somatostatin analogue, is well tolerated when administered as a continuous 7-day subcutaneous infusion in healthy male volunteers.
2012
The Journal of Clinical Pharmacology
Stephan Petersenn
Nicole Unger
Ke Hu
Brigitte Weisshaar
Yilong Zhang
Emmanuel Bouillaud
Karina Hermosillo Reséndiz
Yanfeng Wang
Klaus Mann
Show All
Source
Cite
Save
Citations (28)
Tolerability and Dose Proportional Pharmacokinetics of Pasireotide Administered as a Single Dose or Two Divided Doses in Healthy Male Volunteers: A Single-Center, Open-Label, Ascending-Dose Study
2012
Clinical Therapeutics
Stephan Petersenn
Ke Hu
Mario Maldonado
Yilong Zhang
Janet Lasher
Emmanuel Bouillaud
Yanfeng Wang
Klaus Mann
Nicole Unger
Show All
Source
Cite
Save
Citations (14)
Long-term treatment of Cushing's disease with pasireotide (SOM230): results from a Phase II extension study
2010
Marco Boscaro
Yilong Zhang
Kapildeb Sen
Mario Maldonado
Ulrike Schoenherr
James W. Findling
Show All
Source
Cite
Save
Citations (8)
1